Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 74

1.

HIGD1A Regulates Oxygen Consumption, ROS Production, and AMPK Activity during Glucose Deprivation to Modulate Cell Survival and Tumor Growth.

Ameri K, Jahangiri A, Rajah AM, Tormos KV, Nagarajan R, Pekmezci M, Nguyen V, Wheeler ML, Murphy MP, Sanders TA, Jeffrey SS, Yeghiazarians Y, Rinaudo PF, Costello JF, Aghi MK, Maltepe E.

Cell Rep. 2015 Feb 12. pii: S2211-1247(15)00033-9. doi: 10.1016/j.celrep.2015.01.020. [Epub ahead of print]

2.

Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform.

Kidess E, Heirich K, Wiggin M, Vysotskaia V, Visser BC, Marziali A, Wiedenmann B, Norton JA, Lee M, Jeffrey SS, Poultsides GA.

Oncotarget. 2015 Feb 10;6(4):2549-61.

3.

High-throughput time-resolved FRET reveals Akt/PKB activation as a poor prognostic marker in breast cancer.

Veeriah S, Leboucher P, de Naurois J, Jethwa N, Nye E, Bunting T, Stone R, Stamp G, Calleja V, Jeffrey SS, Parker PJ, Larijani B.

Cancer Res. 2014 Sep 15;74(18):4983-95. doi: 10.1158/0008-5472.CAN-13-3382. Epub 2014 Jun 26.

PMID:
24970478
4.

Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.

Deng G, Krishnakumar S, Powell AA, Zhang H, Mindrinos MN, Telli ML, Davis RW, Jeffrey SS.

BMC Cancer. 2014 Jun 19;14:456. doi: 10.1186/1471-2407-14-456.

5.

Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.

Zhang H, Cohen AL, Krishnakumar S, Wapnir IL, Veeriah S, Deng G, Coram MA, Piskun CM, Longacre TA, Herrler M, Frimannsson DO, Telli ML, Dirbas FM, Matin AC, Dairkee SH, Larijani B, Glinsky GV, Bild AH, Jeffrey SS.

Breast Cancer Res. 2014 Apr 7;16(2):R36. doi: 10.1186/bcr3640.

6.

Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips.

Earhart CM, Hughes CE, Gaster RS, Ooi CC, Wilson RJ, Zhou LY, Humke EW, Xu L, Wong DJ, Willingham SB, Schwartz EJ, Weissman IL, Jeffrey SS, Neal JW, Rohatgi R, Wakelee HA, Wang SX.

Lab Chip. 2014 Jan 7;14(1):78-88. doi: 10.1039/c3lc50580d.

7.

Impact of Navigation on Knowledge and Attitudes About Clinical Trials Among Chinese Patients Undergoing Treatment for Breast and Gynecologic Cancers.

Clair McClung E, Davis SW, Jeffrey SS, Kuo MC, Lee MM, Teng NN.

J Immigr Minor Health. 2013 Aug 21. [Epub ahead of print]

PMID:
23963874
8.

Circulating tumor cells versus tumor-derived cell-free DNA: rivals or partners in cancer care in the era of single-cell analysis?

Kidess E, Jeffrey SS.

Genome Med. 2013 Aug 13;5(8):70. doi: 10.1186/gm474. eCollection 2013. No abstract available.

9.

Colorectal cancer diagnostics: biomarkers, cell-free DNA, circulating tumor cells and defining heterogeneous populations by single-cell analysis.

Kin C, Kidess E, Poultsides GA, Visser BC, Jeffrey SS.

Expert Rev Mol Diagn. 2013 Jul;13(6):581-99. doi: 10.1586/14737159.2013.811896. Review.

PMID:
23895128
10.

Nuclear localization of the mitochondrial factor HIGD1A during metabolic stress.

Ameri K, Rajah AM, Nguyen V, Sanders TA, Jahangiri A, Delay M, Donne M, Choi HJ, Tormos KV, Yeghiazarians Y, Jeffrey SS, Rinaudo PF, Rowitch DH, Aghi M, Maltepe E.

PLoS One. 2013 Apr 30;8(4):e62758. doi: 10.1371/journal.pone.0062758. Print 2013.

11.

Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines.

Powell AA, Talasaz AH, Zhang H, Coram MA, Reddy A, Deng G, Telli ML, Advani RH, Carlson RW, Mollick JA, Sheth S, Kurian AW, Ford JM, Stockdale FE, Quake SR, Pease RF, Mindrinos MN, Bhanot G, Dairkee SH, Davis RW, Jeffrey SS.

PLoS One. 2012;7(5):e33788. doi: 10.1371/journal.pone.0033788. Epub 2012 May 7.

12.

Multiplex molecular analysis of CTCs.

Sieuwerts AM, Jeffrey SS.

Recent Results Cancer Res. 2012;195:125-40. doi: 10.1007/978-3-642-28160-0_11. Review.

PMID:
22527500
13.

A pharmacogenomic method for individualized prediction of drug sensitivity.

Cohen AL, Soldi R, Zhang H, Gustafson AM, Wilcox R, Welm BE, Chang JT, Johnson E, Spira A, Jeffrey SS, Bild AH.

Mol Syst Biol. 2011 Jul 19;7:513. doi: 10.1038/msb.2011.47.

14.

Distinctive responsiveness to stromal signaling accompanies histologic grade programming of cancer cells.

Luciani MG, Seok J, Sayeed A, Champion S, Goodson WH, Jeffrey SS, Xiao W, Mindrinos M, Davis RW, Dairkee SH.

PLoS One. 2011;6(5):e20016. doi: 10.1371/journal.pone.0020016. Epub 2011 May 19.

15.

Adipose levels of polybrominated diphenyl ethers and risk of breast cancer.

Hurley S, Reynolds P, Goldberg D, Nelson DO, Jeffrey SS, Petreas M.

Breast Cancer Res Treat. 2011 Sep;129(2):505-11. doi: 10.1007/s10549-011-1481-7. Epub 2011 Apr 6.

PMID:
21468638
16.
17.

Stem cells in human breast cancer.

Oliveira LR, Jeffrey SS, Ribeiro-Silva A.

Histol Histopathol. 2010 Mar;25(3):371-85. Review.

PMID:
20054808
18.

Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype.

Ameri K, Luong R, Zhang H, Powell AA, Montgomery KD, Espinosa I, Bouley DM, Harris AL, Jeffrey SS.

Br J Cancer. 2010 Feb 2;102(3):561-9. doi: 10.1038/sj.bjc.6605491. Epub 2010 Jan 5.

19.

Focal amplification and oncogene dependency of GAB2 in breast cancer.

Bocanegra M, Bergamaschi A, Kim YH, Miller MA, Rajput AB, Kao J, Langerød A, Han W, Noh DY, Jeffrey SS, Huntsman DG, Børresen-Dale AL, Pollack JR.

Oncogene. 2010 Feb 4;29(5):774-9. doi: 10.1038/onc.2009.364. Epub 2009 Nov 2.

PMID:
19881546
20.

CAMK1D amplification implicated in epithelial-mesenchymal transition in basal-like breast cancer.

Bergamaschi A, Kim YH, Kwei KA, La Choi Y, Bocanegra M, Langerød A, Han W, Noh DY, Huntsman DG, Jeffrey SS, Børresen-Dale AL, Pollack JR.

Mol Oncol. 2008 Dec;2(4):327-39. doi: 10.1016/j.molonc.2008.09.004. Epub 2008 Oct 2.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk